Sanofi’s oral treatment for multiple sclerosis, tolebrutinib, showed promising results in a Phase 3 study, potentially leading to regulatory approval. However, two other studies involving patients in earlier stages of the disease did not show the same benefit. The company’s head of research and development expressed confidence in the positive outcome, stating that it would boost investor confidence in their R&D efforts. While the financial impact may not be substantial, the successful trial serves as a proof-of-concept for the company’s research capabilities. This achievement is seen as a milestone in advancing research and development within Sanofi.
Source link
Multiple sclerosis pill succeeds in key trial, Sanofi says
